top of page
Recruiting

NCT05572515: Phase 3: MajesTEC-9 - Teclistamab alone Versus Pomalidomide-Bort-Dex or Carfilzomib-dex

Updated: Feb 4

  • MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd - RRMM


  • NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)


MajesTEC-9 - Teclistamab alone Vs PVd Vs Kd

NCT05572515: Phase 3: A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-9)


The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.


Sponsor

 

ClinicalTrials.gov Identifier: NCT05572515

Official Title: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

First Posted : October 7, 2022

Click here to see details on ClinicalTrials.gov

 
 

Drug: Teclistamab

Drug: Pomalidomide

Drug: Bortezomib

Drug: Dexamethasone

Drug: Carfilzomib

 

Locations

Locations

Australia

Europe

Belgium

Canada, Alberta

Canada, Nova Scotia

Canada, Ontario

Canada, Quebec

Asia

China

Czechia

Denmark

France

Germany

India

Israel

Italy

Japan

Malaysia

Netherlands

Poland

Portugal

Spain

Sweden

Turkey

United Kingdom

 

RELATED POSTS


TECLISTAMAB STUDIES:


NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)


NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)


NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)


NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma


NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)

 

TALQUETAMAB STUDIES:


NCT03399799: Phase 1 - Talquetamab, a Humanized GPRC5D x CD3 Bis Ab - Ref MM - MonumenTAL-1


NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma


NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma


NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma

 

TECLISTAMAB AND TALQUETAMAB STUDIES:


NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma


NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2







Posts Archive
bottom of page